Combination Phentermine/Topiramate for Obesity Treatment in Primary Care: A Review

References

• . Must A, Spadano J, Coakley EH, . The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529
   PubMed Web of Science ®Google Scholar
• . United States Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med. 2003;139:930–932
   PubMed Web of Science ®Google Scholar
• . Kushner RF. Tackling obesity: Is primary care up to the challenge? Arch Intern Med. 2010;170:121–123
   PubMedGoogle Scholar
• . Hill JO, Wyatt H. Outpatient management of obesity: A primary care perspective. Obes Res. 2002;10:124S–130S
   PubMedGoogle Scholar
• . Christian JG, Bessesen DH, Byers TE, . Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and loss weight. Arch Intern Med. 2008;168:141–146
   PubMed Web of Science ®Google Scholar
• . Ockene IS, Hebert JR, Ockene JK, . Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia. Arch Intern Med. 2009;159:725–731
   Google Scholar
• . Tsai AG, Wadden TA, Rogers MA, . A primary care intervention for weight loss: results of a randomized controlled pilot study. Obesity (Silver Spring). 2010;18:1614–1618
   PubMed Web of Science ®Google Scholar
• . Wadden TA, Volger S, Sarwer DB, . A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med. 2011;365:1969–1979
   PubMed Web of Science ®Google Scholar
• . Blackburn G. Effect of degree of weight loss on health benefits. Obes Res. 1995;3:211S–216S
   PubMedGoogle Scholar
• . NIH, NHLBI Obesity Education Initiative. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Available online: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf
   Google Scholar
• . Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med. 2009;24(9):1073–1079
   PubMed Web of Science ®Google Scholar
• . Leblanc ES, O'Connor E, Whitlock EP, . Effectiveness of primary care-relevant treatments for obesity in adults: A systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:434–447
   PubMed Web of Science ®Google Scholar
• . Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med. 2003;163:1046–1050
   PubMedGoogle Scholar
• . Von Moltke LL, Greenblatt DJ, Ciraulo DA, . Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by d- and l-fenfluramine, but not phentermine. J Clin Psychopharmacol. 1998;18:338–341
   PubMed Web of Science ®Google Scholar
• . Haddock CK, Poston WS, Dill PL, . Pharmacotherapy for obesity: Quantitative analysis of four decades of published randomized controlled trials. Int J Obes. 2002;26:262–273
   PubMed Web of Science ®Google Scholar
• . Silverstone T. Appetite suppressants: A review. Drugs. 1992;43:820–836
   PubMed Web of Science ®Google Scholar
• . Prescribing information for Adipex-P. Teva Pharmaceuticals; July 2012
   Google Scholar
• . Ben-Menachem E, Sander JW, Johanson EH, . Predictors of weight loss in adults with topiramate treated epilepsy. Obes Res. 2003;11:556–562
   PubMedGoogle Scholar
• . Verrotti A, Scaparrotta A, Agostinelli S, . Topiramate-induced weight loss: A review. Epilepsy Res. 2011;95:189–199
   PubMed Web of Science ®Google Scholar
• . McElroy SL, Arnold LM, Shapira NA, . Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:255–261
   PubMed Web of Science ®Google Scholar
• . Nickel MK, Nickel C, Kaplan P, . Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biol Psych. 2005;57(5):495–499
   PubMed Web of Science ®Google Scholar
• . Chengappa KN, Chalasani L, Brar JS, . Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate. An open-label nonrandomized chart review. Clin Ther. 2002;24(10):1576–1584
   PubMed Web of Science ®Google Scholar
• . Kramer CK, Leitao CB, Pinto LC, . Efficacy and safety of topiramate on weight loss: A meta-analysis of randomized controlled trials. Obes Rev. 2011;12:e338–e347
   PubMed Web of Science ®Google Scholar
• . Shank RP, Gardocki JF, Streeter AJ, . An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41:3–9
   PubMed Web of Science ®Google Scholar
• . Khazaal Y, Zullino DF. Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur J Clin Pharmacol. 2007;63:891–892
   PubMed Web of Science ®Google Scholar
• . Wilkes JJ, Nelson E, Osborne M, . Topiramate as an insulin sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab. 2005;288:E617–E624
   Web of Science ®Google Scholar
• . Richard D, Ferland J, Lalonde J, . Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16:961–966
   PubMed Web of Science ®Google Scholar
• . Rubino DM, Gadde KM. A review of topiramate and phentermine: A combined therapeutic approach for obesity. Clin Lipidol. 2012;7:13–25
   Web of Science ®Google Scholar
• . Prescribing information for Topamax. Janssen Pharmaceuticals; October 2012
   Google Scholar
• . Rosenfeld WE, Doose DR, Walker SA, . Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317–323
   PubMed Web of Science ®Google Scholar
• . Doose DR, Wang S-S, Padmanabhan P, . Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540–549
   PubMed Web of Science ®Google Scholar
• . Jones MW. Topiramate—safety and tolerability. Can J Neur Sci. 1998;25:S13–S15
   Web of Science ®Google Scholar
• . Tatum WO, French JA, Faught E, . Postmarketing experience with topiramate and cognition. Epilepsia. 2001;42:1134–1140
   PubMed Web of Science ®Google Scholar
• . Groeper K, McCann ME. Topiramate and metabolic acidosis: A case series and review of the literature. Pediatr Anesthesia. 2005;15:167–170
   PubMed Web of Science ®Google Scholar
• . Bhattacharyya KB, Basu B. Acute myopia induced by topiramate: Report of a case and review of the literature. Neurol India. 2005;53:108–109
   PubMed Web of Science ®Google Scholar
• . Hanchanale VS, Biyani CS, Browning AJ, . Topiramate and the risk of urolithiasis. BJU Int. 2011;107:352–354
   PubMed Web of Science ®Google Scholar
• . Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Exp Rev Pharmacother. 2009;10:921–925
   PubMed Web of Science ®Google Scholar
• . Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009;16:353–358
   PubMedGoogle Scholar
• . Gadde KM, Yonish GM, Foust MS, . A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, on obese adults [abstract]. Obes Res. 2006;14:A17
   Google Scholar
• . Food and Drug Administration. Advisory Committee meeting for Phentermine/topiramate (Qnexa). Division of Metabolism and Endocrinology Products (DMEP) Office of Drug Evaluation II Center for Drug Evaluation and Research, U.S. Food and Drug Adminstation, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218824.pdf
   Google Scholar
• . Allison DB, Gadde KM, Garvey WT, . Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity. 2012;20:330–342
   PubMed Web of Science ®Google Scholar
• . Gadde KM, Allison DB, Ryan DH, . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352
   PubMed Web of Science ®Google Scholar
• . Garvey WT, Ryan DH, Look M, . Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308
   PubMed Web of Science ®Google Scholar
• . Prescribing information for Qsymia. Vivus, Inc; April 2013
   Google Scholar
• . Kroenke K, Spitzer RL, Williams JPW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613
   PubMed Web of Science ®Google Scholar
• . Vivus, Inc. Qsymia: Risk Evaluation and Mitigation Strategy (REMS). http://www.qsymiarems.com/. Accessed July 3, 2013
   Google Scholar
• . American Medical Association. Obesity: Resources for Physicians. http://www.ama-assn.org/ama/pub/physician-resources/public-health/promoting-healthy-lifestyles/obesity/obesity-physician-resources.page? Accessed December 20, 2013
   Google Scholar
• . Hill JO, Wyatt H. Outpatient management of obesity: A primary care perspective. Obes Res. 2002;10:124S–130S
   PubMedGoogle Scholar
• . McInnis KJ, Franklin BA, Rippe JM. Counseling for physical activity in overweight and obese patients. Am Fam Physician. 2003;67:1249–1256
   PubMed Web of Science ®Google Scholar
• . Brownell K. The LEARN Program for Weight Management. Dallas: The Life Style Company; 2000
   Google Scholar